Acuitas Therapeutics v. Genevant & Arbutus: 10-Patent LNP Infringement Dismissed
Acuitas Therapeutics brought a ten-patent infringement action in New Jersey against Genevant Sciences and Arbutus Biopharma, targeting lipid nanoparticle delivery technology underlying Comirnaty and Onpattro. The court granted defendants’ motion to dismiss, closing the case without prejudice after 290 days — leaving the door open for re-filing.
Ten LNP patents, two blockbuster drugs, one motion to dismiss
On August 4, 2023, Acuitas Therapeutics, Inc. filed suit in the U.S. District Court for the District of New Jersey (Case No. 3:23-cv-04200) against Genevant Sciences GmbH and Arbutus Biopharma Corp., asserting infringement of ten U.S. patents directed to lipid nanoparticle (LNP) drug delivery technology. The asserted patents span a broad portfolio — from early-generation LNP compositions (US8058069B2) to more recent formulation and method claims (US11141378B2, US11318098B2, US11298320B2) — and are tied to two high-profile RNA therapeutics: Pfizer/BioNTech’s COVID-19 vaccine Comirnaty and Alnylam’s siRNA therapeutic Onpattro.
Defendants Genevant and Arbutus responded with a Motion to Dismiss (ECF No. 13), which the court granted in a May 20, 2024 order. The complaint was dismissed without prejudice and the matter was marked closed. A dismissal without prejudice does not adjudicate the merits; it means the court found a pleading-level deficiency — such as insufficient factual allegations, standing, or subject-matter issues — without ruling on whether the patents are valid or infringed. Acuitas retains the right to re-file a corrected complaint.
The 290-day timeline from filing to dismissal is consistent with early-stage motion practice and suggests the dispute never reached claim construction or discovery. The public record does not disclose the specific grounds for dismissal — whether procedural, jurisdictional, or substantive pleading deficiencies. The LNP licensing ecosystem surrounding Comirnaty and Onpattro has been heavily contested across multiple venues; this outcome may reflect a strategic pleading recalibration rather than a final resolution of the underlying ownership and licensing questions.
Filing to Dismissed without Prejudice in 290 days
290 days — resolved before trial, faster than the median D.N.J. patent case
Dismissed without prejudice: what the court’s order means for both parties
Motion to dismiss granted — pleading-level defeat, not a merits ruling
A dismissal without prejudice on a motion to dismiss signals the court found the complaint legally insufficient at the pleading stage — not that the patents are invalid or uninfringed. Common grounds include inadequate factual specificity on the infringement allegations, standing defects, or subject-matter jurisdiction issues. No claim construction analysis was reached, and the underlying patent rights remain legally intact.
Rule 12(b) dismissalAcuitas can re-file — but must address the court’s identified deficiencies
Because the dismissal was without prejudice, Acuitas Therapeutics retains the right to file an amended or new complaint curing whatever deficiencies the court identified in its accompanying Opinion. However, re-filing requires Acuitas to address those specific grounds, and defendants will likely renew dismissal arguments. The strategic calculus — including parallel licensing negotiations and related proceedings in other venues — will shape whether and when Acuitas returns to this court.
Re-filing right preservedGenevant and Arbutus win the opening round without a merits determination
Genevant Sciences and Arbutus Biopharma secured dismissal of all ten patent claims without any finding of infringement or validity. This is a significant procedural win — it removes the immediate litigation burden and buys time — but it does not constitute a final judgment. Both defendants remain exposed to re-filed claims and cannot rely on this outcome as a precedential shield against the same patents in future proceedings.
Procedural win, no merits barLNP patent landscape remains unsettled for Comirnaty and Onpattro stakeholders
The LNP technology underpinning both Comirnaty and Onpattro sits at the centre of a complex multi-party licensing dispute. This dismissal without prejudice does not resolve questions of who holds enforceable rights to the core LNP delivery platform. Companies across the mRNA and siRNA therapeutics sector — including vaccine developers and gene therapy players — should treat the broader LNP IP landscape as actively contested, and the Acuitas portfolio as a live enforcement risk pending potential re-filing.
LNP IP landscape unsettledFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Acuitas Therapeutics, Inc. | Company | Biotech IP licensor — holder of US8492359B2 and 9 further LNP delivery patentsSearch in Eureka ↗ |
| Defendant | Genevant Sciences, GmbH | Company | Genevant Sciences GmbH (LNP technology commercializer) and Arbutus Biopharma Corp. (RNA therapeutics developer)Search in Eureka ↗ |
| Co-Defendant | Arbutus Biopharma, Corp. | Company | Search in Eureka ↗ |
| Plaintiff counsel | John D. Tortorella | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kevin Harry Marino | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Marino Tortorella & Boyle, PC | Law Firm | Representing Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | Arnold B. Calmann | Attorney | Counsel for Genevant Sciences, GmbHSearch in Eureka ↗ |
| Defendant counsel | Katherine Ann Escanlar | Attorney | Counsel for Genevant Sciences, GmbHSearch in Eureka ↗ |
| Defendant law firm | Saiber LLC | Law Firm | Representing Genevant Sciences, GmbHSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order is terse but consequential: the motion to dismiss was granted in full, the complaint dismissed without prejudice, and the matter closed in a single order. The ‘without prejudice’ designation is legally significant — it forecloses any estoppel or res judicata argument by defendants in future proceedings. The accompanying Opinion (not reproduced in the public docket excerpt) will contain the court’s reasoning, which Acuitas must address if it re-files. The breadth of the dismissal — covering all ten asserted patents in one order — suggests the deficiency was structural rather than patent-specific.
US8492359B2 and nine further LNP delivery patents — ionizable lipid nanoparticle platform
The ten asserted patents collectively define a broad platform covering ionizable lipid nanoparticle (LNP) compositions and methods used to encapsulate and deliver RNA-based therapeutics — including siRNA and mRNA. The portfolio spans application dates from approximately 2009 (US8058069B2, application No. 12/424367) through 2021 (US11141378B2, US11318098B2, US11298320B2), reflecting an extended prosecution and continuation strategy. LNP technology is the critical enabling delivery mechanism for both siRNA-based Onpattro and mRNA-based Comirnaty, making these patents commercially central to the RNA therapeutics sector.
The Acuitas LNP portfolio sits within a contested ownership triangle involving Acuitas, Arbutus (formerly Protiva), and Genevant (a Roivant-Arbutus spin-out). The strategic significance of these patents extends well beyond Comirnaty and Onpattro — any company developing mRNA vaccines, siRNA therapeutics, or lipid-based gene editing delivery systems potentially operates within the scope of one or more claims. The portfolio’s breadth, multi-generational continuation structure, and connection to two approved blockbuster products make it one of the most commercially watched LNP patent families in the biopharmaceutical sector.
Should your LNP delivery program run an FTO against the Acuitas portfolio?
Any R&D team or product organisation working with ionizable lipid nanoparticle formulations for RNA delivery — whether for vaccines, siRNA, mRNA therapeutics, or gene editing payloads — should treat the ten Acuitas patents as a priority FTO target. The portfolio covers multiple layers of the LNP stack: lipid composition, particle formulation, and delivery methods. Even if your program uses a licensed or proprietary LNP system, understanding whether your specific lipid structures and encapsulation methods fall within these claim scopes is essential before IND filing or commercialisation.
PatSnap Eureka’s FTO Search Agent allows you to run claim-level analysis across all ten Acuitas patents simultaneously, mapping your specific lipid formulations and delivery methods against published claim language and prosecution history. Eureka can also surface related continuation applications not yet in the asserted set, identify relevant prior art that has been cited in parallel IPR proceedings, and flag overlap with Arbutus and Genevant’s own patent portfolios — giving your team a full-spectrum LNP freedom-to-operate picture before regulatory submission.
Run a freedom-to-operate analysis on US8492359B2 to assess your product’s exposure
Run FTO in Eureka →Similar LNP and RNA therapeutics patent infringement cases
Related patent disputes involving lipid nanoparticle delivery technology and RNA therapeutics litigated in U.S. district courts and before the PTAB.
What this case signals for the LNP therapeutics IP landscape
The Acuitas v. Genevant & Arbutus dismissal is one node in a broader, high-stakes contest over foundational LNP delivery patents that underpin the mRNA and siRNA sectors.
A without-prejudice dismissal is a pause, not an exit — monitor for re-filing
The court’s order explicitly preserves Acuitas’s right to re-file. IP teams at Genevant, Arbutus, and companies licensing LNP technology from either party should maintain active docket monitoring. A refiled complaint with corrected pleadings could reintroduce all ten patents and trigger renewed injunction and damages exposure.
Ten-patent assertion signals portfolio depth — each patent warrants independent FTO review
Acuitas asserted patents spanning early LNP compositions to recent method and formulation claims, covering a technology arc from 2009 to 2021 priority dates. Any company working with ionizable lipid nanoparticle delivery systems for RNA therapeutics or vaccines should treat each patent in this portfolio individually — claim scope and expiry dates vary significantly across the ten assertions.
Acuitas v Genevant — key questions answered
The District of New Jersey granted defendants’ motion to dismiss and dismissed the complaint without prejudice on May 20, 2024. The public order does not specify the grounds, but the accompanying Opinion sets out the court’s reasoning. A without-prejudice dismissal means no merits ruling was reached — the court found a pleading-level deficiency. Acuitas retains the right to re-file a corrected complaint.
Acuitas asserted ten U.S. patents: US8492359B2, US8058069B2, US9504651B2, US11141378B2, US8822668B2, US9006417B2, US11318098B2, US9364435B2, US9518272B2, and US11298320B2. All relate to lipid nanoparticle (LNP) delivery technology and are connected to approved RNA therapeutics including Comirnaty (COVID-19 vaccine) and Onpattro (siRNA therapeutic).
The complaint specifically identified Comirnaty (the Pfizer-BioNTech mRNA COVID-19 vaccine) and Onpattro (Alnylam’s patisiran siRNA therapeutic for hereditary transthyretin-mediated amyloidosis) as products whose manufacture or use was alleged to infringe the Acuitas LNP patent portfolio. Both products rely on lipid nanoparticle delivery systems as their core enabling technology.
Yes. A dismissal without prejudice does not bar Acuitas from filing a new or amended complaint. To succeed on re-filing, Acuitas would need to cure the deficiencies identified by the court in its May 2024 Opinion. Defendants would likely renew their motion to dismiss arguments, and any parallel PTAB or licensing developments could influence the strategic timing and structure of a re-filed complaint.
The Acuitas-Genevant-Arbutus dispute is one strand of a multi-party contest over foundational LNP patent rights. Arbutus has separately been involved in IPR proceedings brought by Moderna and Alnylam challenging overlapping LNP patents. Genevant was established to commercialise certain Arbutus LNP assets. This D.N.J. case intersects with that broader ecosystem, and outcomes in PTAB proceedings or licensing negotiations could materially affect any re-filed Acuitas complaint.
PatSnap Eureka searches patents and litigation data to answer instantly.